Recent News

Share
and/or
16 News Items found
In the Clinic
New Trial Advances Cell-Based Immune Therapy for Certain Leukemias
A new study evaluating a cell-based immune therapy to treat an aggressive type of leukemia — the largest study of its kind to date — reports that 88 percent of patients responded to the treatment.
In the News
New Biotech Startup Will Pit the Immune System Against Cancer
Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.
In the Clinic
Cell-Based Immune Therapy Shows Promise in Leukemia Patients
Memorial Sloan Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.
In the Lab
Pictured: ESK1 Monoclonal Antibody
New Molecule Targets Proteins Inside Cancer Cells
Scientists from Memorial Sloan Kettering have collaborated on the discovery of a unique monoclonal antibody, called ESK1, that appears to be effective at targeting and destroying several types of cancer cells.
In the Lab
Pictured: Ross Levine
Researchers Discover Why Some Leukemia Drugs Are Not Sufficiently Effective
Memorial Sloan Kettering researchers have found why certain drugs are not sufficiently effective in treating leukemias called myeloproliferative neoplasms.
Profile
Pictured: Hans-Guido Wendel
Genetic Causes of Blood Cancers Explored
German-born cancer biologist Hans-Guido Wendel is taking advantage of transformative advances in genomics technology to understand key genetic abnormalities in leukemia and lymphoma.